From: High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis
Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Age | 1082 | Â | Â | Â | Â |
 <  = 60 | 601 | Reference |  |  |  |
 > 60 | 481 | 1.253 (0.904–1.738) | 0.175 |  |  |
T stage | 1079 | Â | Â | Â | Â |
T1 | 276 | Reference | Â | Â | Â |
T2&T3&T4 | 803 | 1.886 (1.241–2.867) | 0.003 | 1.609 (0.731–3.542) | 0.237 |
N stage | 1063 | Â | Â | Â | Â |
N0 | 514 | Reference | Â | Â | Â |
N1&N2&N3 | 549 | 2.333 (1.621–3.357) |  < 0.001 | 1.771 (1.123–2.794) | 0.014 |
M stage | 922 | Â | Â | Â | Â |
M0 | 902 | Reference | Â | Â | Â |
M1 | 20 | 8.315 (4.829–14.315) |  < 0.001 | 6.005 (3.115–11.573) |  < 0.001 |
Pathologic stage | 1059 | Â | Â | Â | Â |
Stage I | 180 | Reference | Â | Â | Â |
Stage II&Stage III&Stage IV | 879 | 2.268 (1.325–3.880) | 0.003 | 0.867 (0.316–2.381) | 0.782 |
ER status | 1032 | Â | Â | Â | Â |
Negative | 240 | Reference | Â | Â | Â |
Positive | 792 | 0.622 (0.436–0.887) | 0.009 | 0.700 (0.394–1.244) | 0.224 |
PR status | 1029 | Â | Â | Â | Â |
Negative | 342 | Reference | Â | Â | Â |
Positive | 687 | 0.558 (0.400–0.779) |  < 0.001 | 0.593 (0.343–1.025) | 0.061 |
HER2 status | 715 | Â | Â | Â | Â |
Negative | 558 | Reference | Â | Â | Â |
Positive | 157 | 1.228 (0.712–2.119) | 0.461 |  |  |
radiation_therapy | 986 | Â | Â | Â | Â |
No | 434 | Reference | Â | Â | Â |
Yes | 552 | 0.899 (0.631–1.281) | 0.555 |  |  |
HSPB1 | 1082 | Â | Â | Â | Â |
Low | 541 | Reference | Â | Â | Â |
High | 541 | 1.425 (1.137–1.750) | 0.041 |  |  |